Of the 3048 patients with baseline ET-1 measurements, dapagliflozin reduced the primary outcome of cardiovascular death or worsening HF by 22% (HR, 0.78 [95% CI, 0.66–0.92]). This evidence concerns the gene EDN1 and hydrops fetalis.